MX2009006755A - Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. - Google Patents

Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.

Info

Publication number
MX2009006755A
MX2009006755A MX2009006755A MX2009006755A MX2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A
Authority
MX
Mexico
Prior art keywords
cells
rna viruses
segmented negative
methodology
measles
Prior art date
Application number
MX2009006755A
Other languages
English (en)
Spanish (es)
Inventor
Pierre Charneau
Frederic Tangy
Yves Jacob
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2009006755A publication Critical patent/MX2009006755A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/115Paramyxoviridae, e.g. parainfluenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2009006755A 2006-12-22 2007-12-21 Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. MX2009006755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06292025.1A EP1939214B1 (en) 2006-12-22 2006-12-22 Cells and methodology to generate non-segmented negative-strand RNA viruses
PCT/IB2007/004444 WO2008078198A2 (en) 2006-12-22 2007-12-21 Cells and methodology to generate non-segmented negative-strand rna viruses

Publications (1)

Publication Number Publication Date
MX2009006755A true MX2009006755A (es) 2009-07-31

Family

ID=37831098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006755A MX2009006755A (es) 2006-12-22 2007-12-21 Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.

Country Status (11)

Country Link
US (2) US8586364B2 (enExample)
EP (2) EP1939214B1 (enExample)
JP (2) JP5902371B2 (enExample)
KR (1) KR101469007B1 (enExample)
CN (2) CN101631798A (enExample)
BR (1) BRPI0719469C1 (enExample)
CA (1) CA2673262C (enExample)
DK (2) DK1939214T3 (enExample)
ES (2) ES2423518T3 (enExample)
MX (1) MX2009006755A (enExample)
WO (1) WO2008078198A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1375512T3 (da) 2002-06-20 2009-10-26 Pasteur Institut Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2012038832A2 (en) * 2010-09-24 2012-03-29 Institut Pasteur Generation of replicating chimeric measles virus - retrovirus particles
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
FR2994697B1 (fr) * 2012-08-24 2016-05-13 Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) Souche vaccinale marquee du virus de la peste des petits ruminants, et son procede d'obtention
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
GB2583296A (en) 2015-01-05 2020-10-21 Seagull Biosolutions Pvt Ltd Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3255056A1 (en) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
EP3622078A1 (en) 2017-05-09 2020-03-18 Invectys Recombinant measles vaccine expressing htert
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
CN107557340A (zh) * 2017-09-26 2018-01-09 南京普菲科医药科技有限公司 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用
BR112020009157A2 (pt) 2017-11-09 2020-10-27 Institut Pasteur poliepítopo quimérico, polinucleotídeo, vetor, célula hospedeira e composição imunogênica
EP3727411A2 (en) 2017-12-21 2020-10-28 Institut Pasteur Lassa vaccine
WO2020012037A1 (en) * 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
CN109355301A (zh) * 2018-08-22 2019-02-19 深圳大学 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身
CN111218474A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种副粘病毒的拯救系统和副粘病毒拯救方法
EP3673917A1 (en) 2018-12-28 2020-07-01 Themis Bioscience GmbH Norovirus vaccines
CN109913423A (zh) * 2019-03-27 2019-06-21 扬州大学 一种稳定表达猪德尔塔冠状病毒N蛋白的重组Vero细胞系及应用
EP3865180A1 (en) 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
MX2022009989A (es) 2020-02-13 2022-11-08 Pasteur Institut Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
US20230310581A1 (en) * 2020-04-27 2023-10-05 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
AU2022208199A1 (en) 2021-01-13 2023-07-13 Centre National De La Recherche Scientifique Measles-hiv or measles-htlv vaccine
WO2023230598A2 (en) * 2022-05-27 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Reverse genetics system for feline morbillivirus
EP4501946A1 (en) 2023-07-31 2025-02-05 LoopLab Bio GmbH Self-amplifying biologics for targeted therapy
WO2026013289A1 (en) 2024-07-12 2026-01-15 Institut Pasteur Measles-mumps-rubella (mmr) vaccines
CN120648655B (zh) * 2025-08-21 2026-02-13 内蒙古自治区农牧业科学院 一株t7-293t细胞及其在牛副流感病毒3型感染性克隆拯救病毒中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
DE60033045T2 (de) 1999-10-12 2007-11-08 Institut Pasteur Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
JP2004503233A (ja) 2000-06-16 2004-02-05 インスティティ・パスツール デング熱ウイルスエンベロープ糖タンパク質のプロ−アポトーシスフラグメント
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
DE10234579A1 (de) * 2002-07-30 2004-02-12 Zf Friedrichshafen Ag Getriebe
KR101020532B1 (ko) * 2003-06-09 2011-03-09 와이어쓰 엘엘씨 cDNA로부터의 비분절 네가티브 쇄 RNA 바이러스의 회수를 위한 개선된 방법
EP2361974A1 (fr) 2003-12-02 2011-08-31 Institut Pasteur Utilisation des proteines et des peptides codés par le genome d'une nouvelle souche de coronavirus associé au SRAS
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US20080248067A1 (en) * 2005-04-14 2008-10-09 The University Of Queensland Immunomodulating Compositions and Uses Therefor

Also Published As

Publication number Publication date
EP1939214A1 (en) 2008-07-02
CN104745533A (zh) 2015-07-01
US20100144040A1 (en) 2010-06-10
JP2010512779A (ja) 2010-04-30
WO2008078198A3 (en) 2008-10-30
BRPI0719469A2 (pt) 2014-02-11
ES2423518T3 (es) 2013-09-20
US9499799B2 (en) 2016-11-22
EP2091962B1 (en) 2018-07-04
ES2686168T3 (es) 2018-10-16
DK1939214T3 (da) 2013-10-14
US8586364B2 (en) 2013-11-19
US20140051148A1 (en) 2014-02-20
KR20090103922A (ko) 2009-10-01
BRPI0719469B1 (pt) 2019-07-02
KR101469007B1 (ko) 2014-12-05
CN101631798A (zh) 2010-01-20
EP1939214B1 (en) 2013-07-10
DK2091962T3 (en) 2018-10-08
JP2015015955A (ja) 2015-01-29
JP5902371B2 (ja) 2016-04-13
WO2008078198A2 (en) 2008-07-03
BRPI0719469C1 (pt) 2021-05-25
CA2673262C (en) 2019-03-05
CA2673262A1 (en) 2008-07-03
EP2091962A2 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
MX2009006755A (es) Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.
Meyer et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
MX2024006240A (es) Vacunas contra el metapneumovirus humano.
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
MY182643A (en) Chimeric influenza virus-like particles comprising hemagglutinin
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2012000036A (es) Vacuna.
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
CA3238757A1 (en) Coronavirus vaccine
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2016118642A8 (en) Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2005027825A3 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2010019262A3 (en) Polyvalent vaccine
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
MX2012012681A (es) Secuencias del virus de dengue universales y metodos de uso.
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
PH12016502554B1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2011163628A3 (en) Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration